🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,180 results for “Takeda Pharmaceuticals International AG” Clear

  1. Ponatinib 30 mg QD

    Takeda Pharmaceuticals International AG

    Chronic Phase Chronic Myeloid Leukemia

    phase 3 small molecule terminated

    1 trial

  2. Protein C Concentrate (Human) Vapor Heated

    Takeda Pharmaceuticals International AG

    Protein C Deficiency

    phase 3 small molecule completed

    1 trial

  3. Prucalopride

    Takeda Pharmaceuticals International AG

    Constipation

    phase 3 small molecule terminated

    1 trial

  4. R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm

    Takeda Pharmaceuticals International AG

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  5. RIFAXIMIN , VANCOMYCIN , Entyvio 300 mg powder for concentrate for solution for infusion, AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , CIPROFLOXACIN , METRONIDAZOLE

    Takeda Pharmaceuticals International AG

    Active Chronic Pouchitis

    phase 3 small molecule active

    1 trial

  6. Ramelteon

    Takeda Pharmaceuticals International AG

    Sleep Initiation and Maintenance Disorders

    phase 3 small molecule completed

    2 trials

  7. Ramelteon

    Takeda Pharmaceuticals International AG

    Transient Insomnia

    phase 3 small molecule completed

    1 trial

  8. Ramelteon

    Takeda Pharmaceuticals International AG

    Balance

    phase 3 small molecule completed

    1 trial

  9. Ramelteon SL

    Takeda Pharmaceuticals International AG

    Acute Depressive Episode

    phase 3 small molecule terminated

    1 trial

  10. Ramelteon SL

    Takeda Pharmaceuticals International AG

    Bipolar Disorder

    phase 3 small molecule terminated

    1 trial

  11. Ramelteon SL (Dose 1)

    Takeda Pharmaceuticals International AG

    Bipolar Disorder

    phase 3 small molecule terminated

    1 trial

  12. Ramelteon and Placebo (9 possible combinations total)

    Takeda Pharmaceuticals International AG

    Chronic Insomnia

    phase 3 small molecule completed

    1 trial

  13. Recombinant Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)

    Takeda Pharmaceuticals International AG

    Hemophilia A

    phase 3 mab completed

    1 trial

  14. Recombinant Factor VIIa BI (rFVIIa BI)

    Takeda Pharmaceuticals International AG

    Hemophilia A

    phase 3 mab completed

    1 trial

  15. Recombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM)

    Takeda Pharmaceuticals International AG

    Hemophilia A

    phase 3 mab terminated

    1 trial

  16. Recombinant factor IX

    Takeda Pharmaceuticals International AG

    Hemophilia B

    phase 3 mab completed

    1 trial

  17. Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)

    Takeda Pharmaceuticals International AG

    Primary Immunodeficiency Diseases (PID)

    phase 3 mab completed

    1 trial

  18. Recombinant von Willebrand factor (rVWF)

    Takeda Pharmaceuticals International AG

    Von Willebrand Disease

    phase 3 mab completed

    2 trials

  19. Relugolix

    Takeda Pharmaceuticals International AG

    Uterine Fibroids

    phase 3 small molecule completed

    2 trials

  20. Resatorvid

    Takeda Pharmaceuticals International AG

    Sepsis

    phase 3 small molecule terminated

    2 trials

  21. Rituximab 375 mg/m^2

    Takeda Pharmaceuticals International AG

    Mantle Cell Lymphoma

    phase 3 small molecule completed

    1 trial

  22. SALINE, Fazirsiran

    Takeda Pharmaceuticals International AG

    Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

    phase 3 small molecule active

    1 trial

  23. SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety)

    Takeda Pharmaceuticals International AG

    Primary Immunodeficiency Diseases (PID)

    phase 3 mab completed

    1 trial

  24. SHP465

    Takeda Pharmaceuticals International AG

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    4 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources